Target audiences

This programme is intended for oncologists and practicing clinicians who have an interest in understanding colorectal cancer biology and building individual competencies in the management of the disease.

Files

Final Programme

Learning Journey

Introduction

Access learning resources by clicking the Outcomes tab or scroll down to the Scientific Programme.

Overview

The development of new drugs and the interdisciplinary management of the disease have resulted in a meaningful increase in survival for patients with metastatic colorectal cancer. As the number of therapeutic options increases, insights into the biology of the disease and biomarker-driven therapeutic strategies are expected to improve patients survival and rationalize therapeutic approaches. Recent data reveals that right- and left-sided primary colorectal cancers are clinically and biologically different. Tumor sidedness has significant prognostic and predictive value that will impact on the clinical management of metastatic colorectal cancer patients. Clinical research and medical care are closely related activities and the development of an integrated learning health care system will contribute to generating and applying clinically relevant medical knowledge producing benefits for present and future patients.

Learning objectives

• analyse colorectal cancer biology and molecular biomarkers of clinical relevance
• review biomarker-driven therapeutic strategies in patients with metastatic colorectal cancer
• evaluate the essentials of continuum of care approach for patients with metastatic colorectal
cancer within a multidisciplinary team setting

Scientific programme

Session I Molecular pathology and biomarkers

Chairs: H. Jaafar (UAE), S. Temraz (Lebanon), F. Vafaie Zadeh (Iran)

14.15 L1: Critical pathways in metastatic colorectal cancer (mCRC)
    A. Sobrero (Italy)

14.45 L2: Molecular biomarkers for mCRC
    A. Sobrero (Italy)

15.15    Coffee break

15.30 L3: Evidence-based recommendations for molecular testing of mCRC
    C.H. Köhne (Germany)

16.00    ROUNDTABLE: Key guidelines questions
    J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany)

16.30 L4: Tumor heterogeneity and blood-based biomarkers
    J. Taieb (France)

17.00    Closing remarks

17.15    End of the first day

Session II Treatment decisions in metastatic colorectal cancer (I)

Chairs: H. Jaafar (UAE), S. Temraz (Lebanon), F. Vafaie Zadeh (Iran)

09.00   L5: RAS Wild-type and BRAF Wild-type mCRC
    A. Sobrero (Italy)

09.30   L6: Primary tumor location of RAS wild-type mCRC: left vs right
    C.H. Köhne (Germany)

10.00     WORKING GROUPS: Clinical cases discussion
    J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany)

10.30     Coffee break

10.45   L7: RAS mutated and BRAF mutated mCRC
    J. Taieb (France)

11.15    ROUNDTABLE: Frontline Strategies for Metastatic Colorectal Cancer
    J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany)

12.15     WORKING GROUPS: Clinical cases discussion
    J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany)

13.00    Lunch

Session III Treatment decisions in metastatic colorectal cancer (II)

Chairs: H. Jaafar (UAE), S. Temraz (Lebanon), F. Vafaie Zadeh (Iran)

14.00   L8: Oligometastatic disease
    C.H. Köhne (Germany)

14.30 L9: Therapy after progression
    J. Taieb (France)

15.00     WORKING GROUPS: Clinical cases discussion

    J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany)

15.30 L10: Spotlight - Molecular classification of CRC
    C.H. Köhne (Germany)

15.45 L11: Spotlight - Immunotherapy for mCRC
    J. Taieb (France)

16.00     Concluding remarks
    End of the workshop